Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations

Published 06/06/2024, 18:19
Updated 06/06/2024, 19:40
© Reuters.  Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
NVS
-
RHHBY
-

Benzinga - by Vandana Singh, Benzinga Editor.

Italy’s antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Holdings AG (OTC:RHHBY)-controlled Genentech, for allegedly restricting competition in the sale of an eye drug.

The probe focuses on potential delays in the Italian market launch of Byooviz, a ranibizumab-based drug developed by Samsung Bioepis, due to coordinated strategies by these companies and their subsidiaries in Italy, the Netherlands, and the U.K.

Reuters noted that the Italian watchdog, supported by the finance police, carried out searches in Italy and the Netherlands, with assistance from the Dutch regulator.

Byooviz is a biosimilar of Lucentis, originally developed by Genentech and marketed outside the U.S. by Novartis.

Ranibizumab injections treat neovascular age-related macular degeneration and macular edema in the eye.

The antitrust authority expressed concerns that the suspected delay could have limited drug availability and affected prices for patients, potentially impacting the cost-saving measures of the Italian national health services.

Novartis is cooperating with the investigation, providing the requested information. In an emailed statement to Reuters, a company spokesperson emphasized that Novartis believes it has acted appropriately and in accordance with competition laws, always prioritizing patient interests.

Roche told Reuters it does not comment on regulatory or legal investigations but noted that biosimilar competition is a normal aspect of a treatment’s lifecycle.

The company highlighted the critical role of biosimilars in supporting healthcare systems’ financial sustainability and fostering innovation.

Samsung Bioepis also affirmed its full cooperation with the ongoing investigation, underscoring its commitment to transparency.

Price Action: NVS shares are up 0.58% at $105.97 at the last check on Thursday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo via Wikimedia Commons

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.